Article Details
Retrieved on: 2025-04-08 18:37:02
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the FDA's recent De Novo authorization of Nanosonics’ Coris platform, highlighting insights from Philip Desjardins. It relates to MedTech by addressing regulatory pathways for medical devices and involves key FDA entities.
Article found on: www.arnoldporter.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here